BSEM - BioStem Technologies: Building On Advanced Wound Care Needs
2025-03-17 01:19:57 ET
Summary
- BioStem Technologies' falling share price and rising earnings present a growth opportunity, supported by strong Q4 results, new products, and a potential NASDAQ listing.
- Q4-2024 revenue expected to rise 794% YoY, with full-year net revenue increasing 1,702%, driven by robust product adoption and strategic partnerships.
- Despite operational success, BioStem's stock remains undervalued; a one-year price target of $17.22 reflects a 60.13% increase from its current price.
- Risks include potential clinical trial setbacks, limited public history, low trading volumes, and uncertainties around NASDAQ listing and official Q4 earnings.
Investment thesis
Despite a very strong preliminary Q4-2024 earnings report on January 13, 2025, shares of BioStem Technologies, Inc. ( OTCPK:BSEM ) remain sluggish when they’re not slipping. Share prices did pick up temporarily in the wake of the Q3-2024 earnings, because of outstanding top and bottom-line results, but have since subsided.
I believe a falling share price and rising earnings represent an opportunity for adventurous growth investors. That’s based not only on the preliminary Q4 results, but also on other initiatives, including new products and the possibility of a NASDAQ listing....
BioStem Technologies: Building On Advanced Wound Care Needs